Is Abbott Laboratories (ABT) A Good Stock To Buy Now?

Is ABT a bully banal to buy? We came crossed a bullish thesis connected Abbott Laboratories connected Compounding Dividends’s Substack by TJ Terwilliger. In this article, we volition summarize the bulls’ thesis connected ABT. Abbott Laboratories's stock was trading astatine $109.56 arsenic of March 6th. ABT’s trailing and guardant P/E were 29.45 and 19.30, respectively according to Yahoo Finance.

Abbott Laboratories (ABT) is simply a diversified planetary healthcare institution with a beingness crossed aesculapian devices, diagnostics, nutrition, and established pharmaceuticals, serving some developed and emerging markets. Its aesculapian devices and diagnostics segments thrust astir 70% of revenue, with high-margin products similar the FreeStyle Libre glucose show and bosom repair devices underpinning a durable competitory moat done patents and precocious switching costs.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The nutrition segment, anchored by trusted brands similar Similac and Ensure, benefits from beardown lawsuit loyalty, portion branded generics successful emerging markets supply dependable maturation exposure. Despite this, Abbott faces near-term challenges, including ineligible liabilities implicit specialty babe formula, weakened request pursuing terms increases, declining COVID-testing revenues, and pricing pressures successful China, which person contributed to a banal diminution of astir 15% this twelvemonth and pushed the dividend output toward 2.4%. Management, led by CEO Robert B. Ford, has a way grounds of navigating analyzable markets and acquisitions, including the $21 cardinal Exact Sciences woody aimed astatine entering crab diagnostics.

Abbott’s equilibrium expanse is strong, with a debt-to-equity ratio of 30%, an involvement sum ratio of 75, and robust escaped currency travel generation, enabling continued dividend growth—54 consecutive years and a 5-year CAGR of 9.4%. While near-term headwinds make immoderate uncertainty, the operation of secular tailwinds successful chronic illness management, an aging population, and emerging middle-class markets positions Abbott favorably.

For semipermanent investors seeking resilient healthcare vulnerability and reliable dividends, Abbott represents a compelling opportunity, offering a premix of antiaircraft characteristics, innovation-driven growth, and a proven superior allocation way grounds that could enactment upside arsenic marketplace pressures normalize.

Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel successful May 2025, highlighting wide maturation crossed cardiovascular and diabetes segments and the upcoming diabetes concern spin-off. MDT’s banal terms has appreciated by 12.66% since our coverage. TJ Terwilliger shares a akin presumption but emphasizes Abbott Laboratories’ (ABT) diversified healthcare model, beardown aesculapian instrumentality moat, and resilient dividend growth, offering semipermanent upside.